11b-Hydroxysteroid dehydrogenase type 2 (11b-HSD2) catalyzes the inactivation of cortisol (F) to cortisone (E) in aldosterone target tissues, thereby protects mineralocorticoid receptor from F. Failure of 11b-HSD2 function is the basis of apparent mineralocorticoid excess, and its mild disturbances are suggested to lead to hypertension. The aim of the study was to analyze the 11b-HSD2 activity in hypertensives and healthy volunteers. Glucocorticoids (GCs) profile was estimated to verify whether the disorders of GCs balance may be involved in essential hypertension etiology. Exons and short introns of HSD11B2 were sequenced to evaluate existing mutations and their potential implications in the disease. The identified polymorphisms were assessed in case-control study to determine their relevance to hypertension. No significant differences in values of plasma F/E and UFF/UFE (urinary free F to free E) were observed between hypertensives and controls. The value of (THF þ allo-THF)/(THE þ allo-THE) (urinary tetrahydro-metabolites of F to tetrahydro-metabolites of E) in hypertensives was higher than in normotensives. Logistic regression demonstrated that the increase of one unit of (THF þ allo-THF)/(THE þ allo-THE) value increases the risk of hypertension over 11-fold. Genotyping indicated no hypertension related mutations in the coding region and short introns of HSD11B2.
INTRODUCTION
Unknown etiology refers to over 90% of all diagnosed cases of hypertension. Disturbances of glucocorticoids (GCs) balance are assumed to be a source of primary hypertension in over 30% of cases.
1,2 11b-Hydroxysteroid dehydrogenase type 2 (11b-HSD2) is a key enzyme in GCs metabolism. It catalyzes the inactivation of cortisol (F) to cortisone (E) in aldosterone target tissues, thereby protecting mineralocorticoid receptor (MR) from F, which has similar affinity to MR as aldosterone. Moreover, the level of active GC is about 100 À 1000 times higher than aldosterone concentration. 3 Therefore, the enzymatic prereceptor mechanism is essential to ensure the selectivity of MR to aldosterone. The impairment of 11b-HSD2 activity results in accumulation of F, which stimulates MR and acts as a potent mineralocorticoid. As a consequence Na þ and water retention increases, the intravascular fluid volume expands and finally the blood pressure (BP) elevates. Na þ reabsorption is accompanied by loss of K þ and H þ in the urine. The significance of that phenomenon is emphasized by the fact that stimulation of MR is not controlled by renin À angiotensin À aldosterone system. 4, 5 The human gene HSD11B2 encoding 11b-HSD2 is located on chromosome 16, locus 16q22. [6] [7] [8] The total gene length is about 6.2 kbp and the transcript is 1.879 kbp long. HSD11B2 consists of five subsequent exons, with lengths of 376, 213, 186, 138 and 966 bp, respectively. The first exon is situated about 4.0 kbp from the four other exons, which are separated by short introns (116, 106 and 201 bp). 5 0 UTR is a part of the first exon and contains 112 bp. 3 0 UTR, located in the terminal region of exon 5, is 549 bp long. 6, 7 Failure of 11b-HSD2 activity is the basis of an inherited form of hypertension-apparent mineralocorticoid excess (AME). Mild disturbances in 11b-HSD2 function are suggested to be involved in primary hypertension etiology. 1, 4, [9] [10] [11] [12] [13] Decreased activity of 11b-HSD2 may result from the influence of exogenous (liquorice, carbenoxolone or grapefruit juice intake) and endogenous (action of glycyrrhetinic acid-like factors) inhibitors, 4, [9] [10] [11] 13 as well as from mutations in HSD11B2 gene. Mutations in the gene encoding 11b-HSD2 may lead to default protein structure or disturbances in gene expression and, therefore, to the impairment of enzyme function. 9, 10, 13 The promoter of the HSD11B2 gene is GC-rich region and in over 80% consists of C and G. 8, 14 Two typical CpG-islands can be distinguished in this region, the other two are located in exon 5 and the downstream region of the gene. It was found that HSD11B2 expression is epigenetically modulated in rodent model and cultured human cell lines. 14 There are two ways of assessing 11b-HSD2 activity: genotyping in order to find changes in HSD11B2 gene, and analyzing GCs profile (phenotype) in plasma and urine to calculate specific parameters, such as: plasma F/E, ratio of urinary free cortisol (UFF) to urinary free cortisone (UFE), and ratio of F metabolites to E metabolites. The third parameter is calculated considering urinary levels of tetrahydro-and allo-tetrahydro-metabolites of F (THF and allo-THF) and E (THE and allo-THE). 4, 5, 9, 11, 13, 15 Genetic analysis is necessary to estimate the presence of mutations in the HSD11B2 gene encoding 11b-HSD2.
The aim of the study was to analyze the 11b-HSD2 activity in hypertensive patients (study group) and healthy volunteers (controls). GCs profile was estimated in both groups to verify whether the disorders of GCs balance may be involved in essential hypertension etiology. Moreover, the sequence of exons and short introns of HSD11B2 was analyzed in hypertensives to evaluate existing mutations and their potential implications in the disease. The identified polymorphisms were further assessed in casecontrol study (hypertensives vs normotensives) to determine their relevance to hypertension.
MATERIALS AND METHODS

Study subjects
The study included 149 Caucasians, 79 patients with essential hypertension (48 men and 31 women) and 70 normotensive control subjects (36 men and 34 women). Patients were recruited from inpatients from Wielkopolska region, treated at the Department of Internal Diseases, Metabolic Disorders and Hypertension, Poznan University of Medical Sciences. All participants were at the age of 18-75 years. Patients were considered to have hypertension if they reported using current BP-lowering medication and/or had systolic BPX140 mm Hg and/or diastolic BPX90 mm Hg measured according to the ESH/ESC Guidelines for the Management of Arterial Hypertension. Cases with secondary hypertension, renal failure, Cushing's disease, liver cirrhosis, rheumatic diseases, thyroid dysfunction and other serious diseases were excluded. All participants had no history of serious cardiovascular incidents (heart attack, brain stroke, percutaneous transluminal coronary angioplasty, by-pass). None of the hypertensives was taking GCs or aldosterone antagonists, whereas the control group was not undergoing any kind of treatment during the time of analysis. The study subjects declared that they had not ingested any herbal products or diet supplements during the month preceding the analysis. The study subjects were receiving normal-sodium diet and avoided liquorice and grapefruit.
Blood samples were drawn in the morning (at 8:00-9:00 am) and divided into aliquots. First part was centrifuged and plasma was collected. From the second part of blood sample the genomic DNA was isolated for the genetic analysis. 24-h urine samples were collected following regular procedure (National Institutes of Health recommendations).
Informed consent was obtained from all participants, according to the guidelines of the Declaration of Helsinki. The study protocol was approved by the Ethical Committee at Poznan University of Medical Sciences.
Steroid analysis
Levels of plasma and urinary GCs were determined using previously described HPLC-FLD method. 16 Concentrations of F and E in plasma, as well as amounts of UFF, UFE, THF, allo-THF, THE þ allo-THE in urine were assessed. The total levels of THF, allo-THF, THE and allo-THE were determined after enzymatic hydrolysis with the use of b-glucuronidase under the previously presented conditions. 16 Subsequently, specific parameters were calculated to estimate 11b-HSD2 activity: plasma F/E, UFF/UFE in urine and (THF þ allo-THF)/(THE þ allo-THE) in urine. The following reference ranges were accepted:p4.00 for F/E in plasma; p0.600 for UFF/UFE in urine andp1.40 for (THF þ allo-THF)/(THE þ allo-THE) in urine. 4 Genomic DNA analysis
The genomic DNA of all subjects was extracted from peripheral blood leukocytes using DNA extraction kit (Bio Basic Inc., Markham, Ontario, Canada). PCR amplification of coding region (exons 1-5), 5 0 -and 3 0 -UTR and short introns (2, 3, 4) of HSD11B2 gene was carried out in Bio-Rad thermal cycler (Bio-Rad Laboratories Inc., Hercules, CA, USA). The oligonucleotides for PCR were designed using the free online Primer3 software ( Table 1 ). The PCR analysis was performed in a 13.0 ml reaction mixture containing 1.0 ml of template DNA, 5.0 pmol of each primer (Oligo, IBB PAN, Warsaw, Poland), 2.5 nmol of each dNTP (Bioron GmbH, Ludwigshafen, Germany), 1 
Restriction analysis
Genotyping of two identified polymorphisms was carried out using PCR followed by the appropriate restriction enzyme digestion (PCR-RFLP analysis). The primers used for PCR are presented in Table 1 . The PCR reaction mixture (15.0 ml) contained: 1.0 ml of template DNA, 7.5 pmol of each primer, 2.0 nmol of each dNTP, 0.75 U of DreamTaq DNA Polymerase and 1.5 ml of reaction buffer (Fermentas, Vilnius, Lithuania). The amplification conditions were as follows: initial denaturation at 95 1C for 5 min, 35 cycles of 95 1C for 30 s, annealing temperature (Table 1) for 30 s and 72 1C for 30 s, and final extension at 72 1C for 5 min. Restriction enzyme digestion was performed using TaaI enzyme for c.534G4A polymorphism and HhaI for c.*197C4T according to the manufacturer's instructions (Fermentas, Vilnius, Lithuania). DNA fragments were separated and visualized using ethidium bromide staining on 1.5% agarose gel.
Statistics
Statistical analysis was carried out using Statistica 8.0 software (StatSoft Inc., Tulsa, OK, USA) at significance level a ¼ 0.05. Normality was analyzed using Shapiro À Wilk test. Due to a lack of normal distribution the nonparametric analysis was performed. Mann À Whitney U test was applied for comparisons between patients and controls and Kruskal À Wallis test was used for comparisons between three or more unpaired groups (for example, taking genotype into consideration). Correlations Abbreviation: T ann , annealing temperature.
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were assessed using Spearman test. The differences between hypertensives and controls in the genotype frequencies, as well as in frequencies of cases with F/E, UFF/UFE and (THF þ allo-THF)/(THE þ alloTHE) values exceeding reference ranges were estimated using standard w 2 and Fisher's exact test. Logistic regression was carried out to calculate odds ratio (OR). P-values of less than 0.05 were considered significant.
RESULTS
Steroid profile
The general characteristics of the study participants are presented in Table 2 . The levels of plasma F and E were assessed to calculate F/E ratio. We detected the plasma F/E value exceeding reference range (p4.00) in 45.3% of patients and 41.4% of controls. The w 2 test did not show significant differences between frequencies of cases with F/E44.00 in both groups (P ¼ 0.5256). There were no differences in plasma F concentration and F/E value between hypertensives and controls (Table 3 ). However, the plasma E concentration was significantly higher in controls (P ¼ 0.0007). The Spearman test indicated significant negative correlations between plasma E concentration and BP, both systolic and diastolic (P ¼ 0.0063; R s ¼ À 0.2290; P ¼ 0.0036; R s ¼ À 0.2436, respectively) in a group of all study participants.
The urinary GCs profile was analyzed considering free (unconjugated) F and E as well as the total amount (the sum of free compounds, glucuronides and sulfates) of A-ring reduced metabolites (THF, allo-THF, THE and allo-THE). The UFF and UFE values were higher in healthy volunteers when compared to hypertensives ( Table 3 ). The significant positive correlation (Spearman test) was observed in controls between UFF and systolic BP (P ¼ 0.0416; R s ¼ 0.2497). The median of UFF/UFE was higher in hypertensives than in controls but the difference was not statistically significant (Table 3) . Positive correlation between UFF/UFE and systolic BP (P ¼ 0.0374; R s ¼ 0.2548) was discovered in controls. The UFF/UFE value exceeding the reference range (p0.600) was observed in 15.9% of hypertensives and in 7.1% of controls. However, the w 2 test indicated the difference to be nonsignificant (P ¼ 0.0701).
The sum of urinary levels of THF and allo-THF was significantly higher in the study group than in controls (Table 3) . No difference was found in the sum of THE and allo-THE between both groups. The Spearman test indicated the significant positive correlations between THF þ allo-THF and both systolic and diastolic BP (P ¼ 0.0016; R s ¼ 0.3777; P ¼ 0.0033; R s ¼ 0.3539 respectively) in controls, but not in patients. The significant positive correlation was observed between body mass index (BMI) and amount of urinary A-ring reduced metabolites of both F and E. The dependence BMI-the amount of (THF þ allo-THF) was stronger in normotensives than in patients: P ¼ 0.0001, R s ¼ 0.4522 and P ¼ 0.0074, R s ¼ 0.3129, respectively. Similar situation was found considering the correlation BMI-amount of (THE þ allo-THE): Po0.0001, R s ¼ 0.5220 in controls and P ¼ 0.0009, R s ¼ 0.3841 in hypertensives. The significant positive correlations were observed between the amount of (THF þ allo-THF) and age (P ¼ 0.0362; R s ¼ 0.2474) as well as between the ratio (THF þ allo-THF)/ (THE þ allo-THE) and age (P ¼ 0.0112; R s ¼ 0.2974) in hypertensive patients. Taking into consideration all study subjects, correlations were found between the ratio (THF þ allo-THF)/(THE þ allo-THE) as well as the amount of (THF þ allo-THF) and age (P ¼ 0.0001, R s ¼ 0.3147 and P ¼ 0.0179, R s ¼ 0.1985, respectively). The (THF þ allo-THF)/(THE þ allo-THE) value was significantly higher in patients than in healthy volunteers (Table 3) . Moreover, (THF þ allo-THF)/(THE þ alloTHE) value exceeded the reference range (p1.40) in 22.2% cases from the study group and was only slightly increased (1.77) in one healthy volunteer (1.4%). The Fisher's exact test indicated the significant difference between frequencies of cases with (THF þ allo-THF)/(THE þ allo-THE)41.40 (P ¼ 0.0001) in both groups. Moreover, there was a positive correlation between (THF þ allo-THF)/(THE þ allo-THE) and systolic BP (Spearman test;
The serum aldosterone concentration (recumbent), plasma renin activity (PRA) and aldosterone to PRA ratio were determined in hypertensives and amounted 89. 8 Abbreviation: NS, non significant. All values presented as medians and interquartile ranges (lower quartile-upper quartile).
11b-Hydroxysteroid dehydrogenase 2 in hypertension K Kosicka et al interquartile ranges). In 62% of the hypertensives the PRA value was below 1.00 ng ml À 1 h À 1 and those subjects were considered as low-renin essential hypertensives. 17 The Mann À Whitney U test did not indicated (P40.05) the significant differences between neither plasma and urinary levels of GCs nor the parameters F/E, UFF/UFE and (THF þ allo-THF)/(THE þ allo-THE) between low-renin and normal-renin hypertensives. We did not find the correlations (Spearman test) between aldosterone, PRA or aldosterone/PRA ratio and GCs profile. The Fisher's exact test did not indicate the difference in distribution of c.534GA and c.*197CT genotype between low-renin and normal-renin essential hypertensives.
Logistic regression was carried out to verify the role of 11b-HSD2 activity, expressed as plasma F/E, UFF/UFE and (THF þ allo-THF)/(THE þ alloTHE) values, in hypertension. The statistical analysis did not indicate that plasma F/E and UFF/UFE values are associated with the disease appearance (P40.05, OR ¼ 1.14 and P40.05, OR ¼ 2.24, respectively). However, the logistic regression showed that the increase of (THF þ allo-THF)/(THE þ allo-THE) value results in significantly higher risk of hypertension (Po0.0001, OR ¼ 11.34).
Genetic analysis
The direct sequencing was carried out in samples obtained from 76 hypertensive patients and 27 controls. Six different singlenucleotide polymorphisms were detected: c.468C4A (Thr156Thr; rs5479), c.534G4A (Glu168Glu; rs45483293), c.591C4A (Leu197-Leu), c.1164C4T (Asp388Asp; rs45578842), c.*197C4T (rs56406870) and c.*465A4G (rs72650128). No alterations were found in the short intronic sequences. Three mutations (c.591C4A, c.1164C4T and c.*465A4G) were observed in single cases, the first one in healthy volunteer, the other two in hypertensives. Two single-nucleotide polymorphisms (c.468C4A and c.534G4A) were found together in five hypertensives and one healthy subject. All participants with the c.468CA genotype also showed the c.534GA polymorphism. No cases possessing only one of these two polymorphisms were detected. The substitution in 3 0 UTR c.*197C4T was observed in seven patients and two controls. Two of the reported mutations (c.534G4A and c.*197C4T) were further analyzed in PCR-RFLP.
The restriction analysis was carried out to estimate the polymorphisms relevance to hypertension. All samples from the study group (n ¼ 76) and the control group (n ¼ 70) were analyzed to determine the frequency and the homo-or heterozygosity of the genotypes. Restriction analysis confirmed the c.534G4A and c.*197C4T polymorphisms detected in sequencing. Moreover, the C4T substitution in c.*197 was found in five subsequent samples, which were not sequenced previously. All observed changes were heterozygous. The genotype frequencies are summarized in Table 4 . The observed frequencies were distributed in agreement with the Hardy À Weinberg equilibrium. The frequency of c.534A allele was low (0.033 in hypertensives and 0.007 in controls) and no cases with AA genotype were observed, therefore the GA and AA genotypes were considered together. Similarly, the frequency of c.*197T allele was low (0.046 in patients and 0.050 in controls) thus the CT and TT genotypes were also considered together (Table 4 ). The Fisher's exact test indicated no differences between genotypes and alleles frequencies in the study group vs controls. The systolic and diastolic BP and steroids profile did not differ in hypertensives and controls considering genotypes c. 
DISCUSSION
The explanation of hypertension etiology has been the pervaded problem for the scientists for many years because of its complexity. The fact that many mechanisms are involved together in BP regulation makes more difficult the attempts to find the solution. In our study we concerned the influence of GCs profile reflecting the activity of 11b-HSD as well as genetic alterations in the HSD11B2 gene on hypertension development. Therefore, it was possible to verify if the phenotype (the levels of endogenous GCs in plasma and urine) is fully reflected in the genotype (genetic alterations).
In the present study, we observed the significant difference in plasma E concentration between hypertensives and controls, whereas plasma F concentration was similar in both groups. It may indicate that the F to E inactivation by 11b-HSD2 is impaired in hypertension. There was no significant difference in plasma F/E value between the study and control groups (3.82 vs 3.64). Therefore, we did not confirm the results presented by Krall et al. 18 and Carvajal et al. 17 who observed significantly higher values of F/E in Chilean hypertensives when compared with healthy volunteers. The significant correlation between UFF and systolic BP in controls observed in this study confirms the assumption that GCs strongly affect the BP. 2, [19] [20] [21] These results are in agreement with the previous observations presented by Krall et al. 18 and Litchfield et al. 1 They found higher amounts of UFF in hypertensives than in controls 1, 18 but there was no correlation between UFF and BP. 18 The UFF/UFE ratio is considered to be the most reliable parameter in assessment of 11b-HSD2 activity. 5, 10, 11, 13 In the presented study we observed the higher median value of UFF/UFE in hypertensives than in controls (0.363 vs 0.330) but the difference was non-significant (Table 3) . Mariniello et al. 22 reported the higher UFF/UFE values in group of hypertensive Italians than in healthy volunteers. Agarwal et al. 23 found significantly higher UFF/UFE ratios in hypertensives with salt sensitivity than in salt resistant hypertensives. In our study we found the correlation between UFF/UFE value and systolic BP in controls. It indicates the 11b-Hydroxysteroid dehydrogenase 2 in hypertension K Kosicka et al dependence between GCs balance and BP, but the statistics did not confirm that UFF/UFE can be a good biochemical marker of hypertension in a general population. However, we observed the distinct tendency to higher values of UFF/UFE in hypertension compared with healthy subjects. Therefore, that issue needs to be further investigated. The significantly higher amount of urinary THF þ allo-THF was detected in study group than in controls. The higher F level is observed in organism, the more reduced metabolites (THF and allo-THF) are produced. Moreover, the observed dependences between THF þ allo-THF and systolic and diastolic BP confirm that higher GCs level results in BP increase. That could indicate that hypertension is associated with increased GCs levels due to impaired 11b-HSD2 function. However, the interfering factors like BMI and age that might influence the GCs profile (especially the amounts of reduced metabolites) have to be considered. The dependence between reduced metabolites of F and E and BMI was found in the study. It may be connected to higher F secretion in obesity (11b-HSD1 activity in adipose tissue) and therefore the augmented F metabolism by reductases. 24 Such associations were found neither between BMI and F or E plasma level nor between BMI and UFF or UFE. Similar results concerning GCs levels with regard to BMI value were presented by Stewart et al. 25 The significant correlations between the ratio (THF þ allo-THF)/(THE þ allo-THE) as well as the amount of (THF þ allo-THF) and age were observed in the study. It may confirm the assumption that the significant differences in GCs profile among hypertensives may result from age (the age in the study group was higher than in controls). That might indicate that reduced 11b-HSD2 activity could be a risk factor contributing to the rising prevalence of arterial hypertension in elderly. However, there were no correlations between age and neither plasma F and E levels and F/E, nor UFF, UFE and UFF/UFE ratio. The correlation between low-renin essential hypertension and GCs metabolism was previously presented by Carvajal et al. 17 Our results did not confirm the previously reported observations because no differences in 11b-HSD2 activity were found between low-renin and normal-renin essential hypertension. We did not find any correlations between GCs profile and serum aldosterone, PRA or aldosterone/PRA ratio. The logistic regression was applied to verify if the higher (THF þ allo-THF)/(THE-alloTHE) value is associated with the more frequent appearance of hypertension. We found the ratio (THF þ allo-THF)/(THE þ alloTHE) to be the potential biochemical marker of hypertension. The possible application of the parameter in screening test needs to be considered, especially that the increase of one unit of its value results in over an 11 times higher risk of hypertensive disease (OR ¼ 11.34). The influence of BMI and age on (THF þ allo-THF)/(THE þ allo-THE) value should be remembered, so the complete GCs profile analysis (with UFF/UFE and plasma F/E) seems to be the most reliable way to assess the risk of hypertension. However, it can be assumed that disturbances in GCs balance indicated by (THF þ allo-THF)/(THE þ allo-THE) may be considered as important risk factor of hypertension. The values of (THF þ allo-THF)/ (THE þ allo-THE) over the reference range were observed in patients with AME who demonstrated partially diminished or a lack of 11b-HSD2 activity. 15, 23, [26] [27] [28] [29] The obtained results substantiate the assumption presented by many authors 1, 4, [9] [10] [11] [12] [13] that mild disturbances of 11b-HSD2 function may cause hypertension, especially considering cases with hypokalemia and low aldosterone. Moreover, the GCs profile could be easily analyzed for evaluation of hypertension risk factor associated with aging and obesity.
Up to now, over 30 mutations were reported in patients with AME. Most of the mutations were found in exons 3-5, but exons 3 and 4 seem to be crucial when considering genetic alterations. 5, 9, 10, 13 The explanation of the genetic basis of AME determined the path for HSD11B2 gene analysis in patients with essential hypertension. So far, the correlation between the length of CA repeat microsatellite in intron 1 and 11b-HSD2 expression was demonstrated in hypertensive patients with low PRA 17 and salt-sensitivity. 23 The significance of alterations in coding region of HSD11B2 is unclear due to different or even contradictory results. In present study, sequencing of the coding region, UTRs and short introns of the HSD11B2 indicated that all cases with c.468C4A alteration (Thr156Thr) in exon 2 possessed c.534G4A polymorphism (Glu178Glu) in exon 3. These results are in agreement with previously presented reports by Mariniello et al. 22 The c.468C4A and c.534G4A polymorphisms were also found together in the study including Italian population with greater frequency of the former polymorphism in hypertensives than in normotensives. Polymorphism c.468C4A without c.534G4A was found in none of the hypertensive patients and in only one normotensive volunteer. Moreover, c.534GA without c.468CA was detected in none of hypertensives but 5% of normotensive participants of the study possessed c.468CC/ c.534GA genotype. 22 Therefore, the association between those two polymorphisms in the HSD11B2 gene and hypertensive disease needs to be further investigated. Especially that those alterations do not affect protein structure and their possible role in gene expression is still unclear.
In RFLP analysis we noticed the clear tendency to greater frequency of c.534GA genotype in hypertensive patients than in control subjects, but the difference was not statistically significant. In contrast, the c.*197C4T alteration in 3 0 UTR (exon 5) had very similar distribution in study group and controls. Therefore, its possible association with hypertension seems to be doubtful. The polymorphism based on G to A substitution in codon 178 was previously reported by various authors who studied its association with hypertension and renal insufficiency. 12, 17, 22, [30] [31] [32] However, the results are equivocal. The genotype c.534GA was found to be more frequent in Caucasians with end stage renal disease than in healthy volunteers 32 but that connection was not confirmed in other studies. 30 The study on Swedish 12 and French 31 populations demonstrated similar frequencies of c.534G4A polymorphism in the study and control groups. The results obtained in our study indicate the very clear tendency to greater frequency of c.543G4A polymorphism appearance in hypertensives than in healthy volunteers. However, the conclusions from statistical analysis are distinct, thus future investigation including greater cohort seems to be warranted.
Despite the presence of indicators of endogenous F metabolism disturbances in hypertensives, the obtained results were not fully reflected in genotypes of those patients. We did not find differences in steroid profile between cases with wild c.534GG genotype compared with c.534GA. Similarly, there was no connection between the possession of heterozygous c.*197CT genotype and GCs balance. It indicates that those substitutions do not influence the enzyme function. Thus, we did not confirm the results obtained by Mariniello et al. 22 who found that the patients with c.534G4A polymorphism had significantly higher UFF/UFE ratio. They hypothesize this exonic alteration may influence splicing efficiency and accuracy and therefore affect gene expression. We suggest that the more probable explanation of 11b-HSD2 activity differences between hypertensives and normotensive subjects seems to be of the epigenetic nature. DNA methylation is the most probable mechanism that would change HSD11B2 expression with regard to presence of CpG islands in the gene structure. 14, 33 It was previously demonstrated that the HSD11B2 expression is modulated epigenetically in rodent model as well as in cultured human cell lines. The hypermethylation of CpG-islands within the promoter and exon 1 was found to be associated with decreased HSD11B2 gene expression.
14 Moreover, the clear link was shown between elevated methylation in HSD11B2 promoter in peripheral blood mononuclear cells DNA and hypertension. 34 In conclusion, the study confirmed that the complete GCs profile analysis is useful in assessing the risk of hypertension. The elevation 11b-Hydroxysteroid dehydrogenase 2 in hypertension K Kosicka et al of (THF þ allo-THF)/(THE þ allo-THE) value should be considered as significant indicator of higher risk of hypertension that might distinguish the population more susceptible to the disease development. The influence of interfering factors like age and obesity on the GCs profile has to be considered. The results of the study did not indicate any polymorphisms in coding region of HSD11B2 that would be associated with hypertension. This fact substantiates the previous observations, because most studies have failed to demonstrate the presence of mutations in the HSD11B2 coding region and the disease in an unselected hypertensive population. However, the link between c.534G4A and hypertension remains unclear and needs to be further investigated. Another possible mechanism that could influence the 11b-HSD2 activity seems to be the epigenetic modulation of HSD11B2 expression.
